Lidco (LID)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 20.1 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 3.14 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Jan | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014E | 2015E | CAGR / Avg | |
| Revenue | £m | |||||||||
| Operating Profit | £m | |||||||||
| Net Profit | £m | |||||||||
| EPS Reported | p | |||||||||
| EPS Normalised | p | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | p | |||||||||
| Capex ps | p | |||||||||
| Free Cashflow ps | p | |||||||||
| Dividends | ||||||||||
| Dividend ps | p | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | £m | |||||||||
| Working Capital | £m | |||||||||
| Net Fixed Assets | £m | |||||||||
| Net Debt | £m | |||||||||
| Book Value | £m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | p | +1.2% | ||||||||
FINANCIAL BRIEF: For the fiscal year ended 31 January 2013, LiDCO Group plc revenues increased 1% to L7.2M. Net loss totaled L117K vs. income of L15K. Revenues reflect United Kingdom segment increase of 33% to L4.9M. Net loss reflects United States segment income decrease of 42% to L551K, Rest of World segment income decrease of 43% to L276K, Continental Europe segment income decrease of 36% to L313K. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Jan '13) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: |
LiDCO Group Plc is a manufactures of hemodynamic monitoring equipment and disposables. The principal activity of the Company is the development, manufacture and sale of cardiac monitoring equipment. It operates in one segment, the supply of monitors, consumables and support services associated with the use of the LiDCO’s cardiac monitoring equipment. Its products include LiDCOplus and LiDCOrapid. The Company's markets its products in United States, United Kingdom and Continental Europe. Its wholly owned subsidiary is LiDCO Limited. During the year ended January 31, 2011, the Company's new products development was introduced includes a software upgrade to the LiDCOrapid, including a module to expand access to blood pressure data; a translation facility to convert information from English into 22 languages, and communication with Philips and GE hospital information systems.
Directors: Terence O'Brien (CEO) , Paul Clifford (Fin. Dir.) , John Barry (Exec. Dir.) , John Rowland (Secy.) ,
No. of Employees: 42 No. of Shareholders: n/a
| Last Annual | January 31st, 2013 |
| Last Interim | January 31st, 2013 |
| Shares in Issue | 193,640,000 |
| Free Float | 127.7m (66.0%) |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | 16 ORSMAN ROAD, LONDON, N1 5QJ, United Kingdom |
| Web | http://www.lidco.com/ |
| Phone | +44 20 77491521 |
| Contact | Rob Lamb (Secy.) |
| Registrar | Capita Registrars (Kent) |
| Auditors | Grant Thornton UK LLP |
| 17th May | Notice of AGM and posting of Annual Report |
| 9th May | LiDCOrapidv2 incorporated in NHS Foundation Trust |
| 8th May | Exercise of Share Options |
| 23rd Apr | Preliminary Results |
| 26th Mar | US FDA clears for sale LiDCOrapidv2 |
| 15th Mar | Grant of LiDCOrapid user interface patent in Japan |
Recent ↓
